|
Press Releases |
|
|
|
Friday, August 25, 2023 |
|
Hua Medicine Announces 2023 Interim Results |
First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
Monday, October 10, 2022 |
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
Tuesday, June 7, 2022 |
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
Friday, May 13, 2022 |
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
Thursday, March 17, 2022 |
|
Hua Medicine Announces 2021 Annual Results |
Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
Sunday, September 26, 2021 |
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
Wednesday, September 15, 2021 |
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
Thursday, August 19, 2021 |
|
Hua Medicine Announces 2021 Interim Results |
Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
Friday, April 23, 2021 |
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
Friday, March 19, 2021 |
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Yee Hop Holdings' (1662.HK) Subsidiary APEL Triumphs with Three Medals at the International Exhibition of Inventions Geneva
May 6, 2024 18:42 HKT/SGT
|
|
|
2024 CAP Consumer Survey Shows Increase in Piracy on Social Media and Messaging Platforms in Asia Pacific
May 6, 2024 18:00 HKT/SGT
|
|
|
SMEStreet Celebrates 10 Years of Serving Indian MSMEs
May 6, 2024 17:20 HKT/SGT
|
|
|
World Blockchain Summit: Pioneering Insights and Strategic Partnerships Ignite in Dubai
May 6, 2024 16:50 HKT/SGT
|
|
|
Future of Video in India Sees Much Optimism for Growth with Technology as the Enabler for the Consumer
May 6, 2024 15:40 HKT/SGT
|
|
|
Rockbird media Presents Retail & E-commerce Summit Asia 2024 - 'Retail Revolution: Setting the Landscape Ablaze' in Manila
May 6, 2024 15:00 HKT/SGT
|
|
|
Rockbird media Presents HR Leaders & HR Tech Strategy Meeting 2024: 'Rehumanizing Work with Emerging Technologies' in Manila
May 6, 2024 14:00 HKT/SGT
|
|
|
CropLife Asia announces new Office Bearers for 2024
May 6, 2024 13:00 HKT/SGT
|
|
|
JBM Healthcare Issues Positive Profit Alert
May 5, 2024 11:00 HKT/SGT
|
|
|
Aemetis to Review First Quarter 2024 Financial Results on May 9, 2024
May 4, 2024 01:00 HKT/SGT
|
|
|
Peapack Private Hires Jerry Dominguez as Senior Managing Director
May 4, 2024 01:00 HKT/SGT
|
|
|
UVify Sets New Guinness World Record With 5,293 IFO Drones in Spectacular Aerial Display
May 4, 2024 00:00 HKT/SGT
|
|
|
Singapore's top general insurer debuts trading on Asia's leading digital exchange, AltaX
May 3, 2024 10:30 HKT/SGT
|
|
|
Nephros Schedules First Quarter 2024 Financial Results Conference Call
May 3, 2024 08:31 HKT/SGT
|
|
|
Nass Valley Gateway Ltd Announces It Will File Its 2023 EOY Audited Financials by June 28th, 2024, Within the Extension Granted by the BCSC
May 3, 2024 08:26 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|